TMJ denials in California external review
In the California DMHC record, independent physician reviewers decided 95 published external-review cases involving TMJand overturned the plan’s denial in 54.7%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for TMJ
| Category | Decisions | Overturned |
|---|---|---|
| Botox Injection | 23 | 52.2% |
| Jaw Surgery | 12 | 75% |
| MRI | 4 | 50% |
| SCP Consult Refer | 3 | 100% |
| Acupuncture | 3 | 33.3% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 69 | 63.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 24 | 33.3% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for all or any of the temporomandibular joint (TMJ) specialist services including evaluation of new patient, craniofacial and maxillofacial procedure of the head, other musculoskeletal procedures of the head; and/or cast supplies and all or any of the office visits for orthotic device evaluation and adjustment. In this case, the patient had a diagnosis of TMJ arthralgia that is consistent with intra and extra-articular disorder of the TMJ complex. Extra-articular disorders can manifest as generalized tenderness of the masticatory and cervical musculature. The patient exhibited jaw clicking, jaw locking, limited mouth opening, neck pain, headaches, migraines, and morning head pain.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Botox injections every 12 weeks.Botox is a neurotoxin that inhibits acetylcholine release at the neuromuscular junction, effectively reducing muscle hyperactivity. Botox has been used to treat patients with refractory bruxism and oromandibular dystonia who have failed to respond to adequate attempts at first-line therapies. A study demonstrated that Botox can significantly improve pain, jaw function, and muscle activity in patients with sleep bruxism and temporomandibular (TMJ) symptoms, with a strong safety profile. A randomized, placebo-controlled trial showed that Botox led to statistically significant improvements in sleep bruxism frequency and facial pain, with no serious adverse events.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Botox injections. There is a lack of controlled studies, single or double-blind, that prove the efficacy of botulinum toxin used in the treatment of temporomandibular joint disorders. Temporomandibular joint disorders represent a complex and multifaceted set of conditions affecting the jaw joint and muscles controlling jaw movement. The treatment for temporomandibular joint disorders varies, ranging from conservative therapies to surgical interventions. Botulinum toxin, primarily known for its use in cosmetic procedures, has been explored as a treatment for temporomandibular joint disorders. The use of botulinum toxin in temporomandibular joint disorders is predicated on its ability to reduce muscle activity, thereby alleviating pain and dysfunction.
Physician 1: The patient is a 35-year-old female with temporomandibular joint dysfunction and associated head and neck pain. Treatment with physical therapy produced significant improvement in symptoms. The submitted evidence does not demonstrate that she has been treated with a combination of dental occlusal splinting, analgesics and physical therapy. Orthotic splinting and occlusal equilibration has not been performed and the patient’s symptoms have recurred.A request has been made for authorization and coverage for an electromyography (EMG).
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving TMJ, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY